Condition (MeSH)
Akathisia, Drug-Induced
ClinicalTrials.gov lists 3 trials for Akathisia, Drug-Induced or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with Akathisia, Drug-Induced itself; the rest are tagged with a narrower condition beneath it.
When did Akathisia, Drug-Induced trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2007 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Akathisia, Drug-Induced trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Observational | 1 |
How many Akathisia, Drug-Induced trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Akathisia, Drug-Induced trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 2 |
Which serious adverse events do Akathisia, Drug-Induced trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dehydration | 1 | 1 |
| Diarrhoea | 1 | 1 |
| Nausea | 1 | 1 |
| Vomiting | 1 | 1 |
Which publications cover Akathisia, Drug-Induced? (72)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Adult Emergence Agitation: A Veteran-Focused Narrative Review. | Anesthesia and analgesia | 2021 | Yes |
| Incidence of akathisia after postoperative nausea and vomiting prophylaxis with droperidol and ondansetron in outpatient surgery: A multicentre controlled randomised trial. | European journal of anaesthesiology | 2018 | Yes |
| Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. | The Journal of clinical psychiatry | 2017 | Yes |
| Predicting morphine related side effects in the ED: An international cohort study. | The American journal of emergency medicine | 2017 | Yes |
| Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trial. | Addiction (Abingdon, England) | 2017 | Yes |
Showing 5 of 72 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.